| Title |
Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms
|
|---|---|
| Published in |
International Journal of Hematology, July 2016
|
| DOI | 10.1007/s12185-016-2058-3 |
| Pubmed ID | |
| Authors |
M. Monika Belickova, Michaela Dostalova Merkerova, Hana Votavova, Jan Valka, Jitka Vesela, Barbora Pejsova, Hana Hajkova, Jiri Klema, Jaroslav Cermak, Anna Jonasova |
| Abstract |
Azacitidine (AZA) is a hypomethylating drug used to treat disorders associated with myelodysplasia and related neoplasms. Approximately 50 % of patients do not respond to AZA and have very poor outcomes. There is thus great interest in identifying predictive biomarkers for AZA responsiveness. We searched for specific genes whose expression level was associated with response status. Using microarrays, we analyzed gene expression patterns in bone marrow CD34(+) cells in serial samples from 32 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia with myelodysplasia-related changes before and during the AZA therapy. At baseline, a comparison of the responders and non-responders showed 52 differentially expressed genes (P < 0.01). Functional annotation of the deregulated genes revealed categories primarily related to ribosomes and pathways associated with proliferation. The expression level of RPL28 correlated with overall survival. We identified altered expression in 167 genes in responders, 26 genes in non-responders with stable disease, and 13 genes in non-responders with disease progression using paired t test of expression levels in patients before and during treatment. Our data indicate that AZA treatment failure is associated with the up-regulation of ribosomal genes/pathways that are likely related to intensive proteosynthesis in proliferative/neoplastic cells of non-responders. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Egypt | 1 | 33% |
| United States | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Peru | 1 | 4% |
| Unknown | 26 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 22% |
| Student > Ph. D. Student | 3 | 11% |
| Student > Master | 2 | 7% |
| Student > Bachelor | 2 | 7% |
| Professor > Associate Professor | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 10 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 8 | 30% |
| Medicine and Dentistry | 3 | 11% |
| Agricultural and Biological Sciences | 3 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Philosophy | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 11 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 July 2016.
All research outputs
#14,857,184
of 22,880,691 outputs
Outputs from International Journal of Hematology
#654
of 1,395 outputs
Outputs of similar age
#216,806
of 355,133 outputs
Outputs of similar age from International Journal of Hematology
#6
of 26 outputs
Altmetric has tracked 22,880,691 research outputs across all sources so far. This one is in the 33rd percentile – i.e., 33% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,395 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 355,133 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.